Neurology Identifying the Role of Disease-Modifying Drugs in the Treatment of Patients With Multiple Sclerosis expert roundtables By David A. Hafler, MD; Dean Wingerchuk, MD, FRCP(C), MSc; Staley Brod, MD
Neurology Unmet Need of Cognitive Decline in Patients With Multiple Sclerosis clinical topic updates By Dean Wingerchuk, MD, FRCP(C), MSc
Neurology Reducing Relapse Rates and Disease Progression With Disease-Modifying Therapies in Patients With Multiple Sclerosis clinical topic updates By Dean Wingerchuk, MD, FRCP(C), MSc
Neurology Treatment Goals and Strategies for Patients With Primary Progressive Multiple Sclerosis expert roundtables By Aaron Miller, MD; Patricia K. Coyle, MD, FAAN, FANA; Scott Newsome, DO, MSCS, FAAN
Neurology Epstein-Barr Virus Associated With Greater Multiple Sclerosis Susceptibility Among Whites, Blacks, and Hispanics clinical study insights By Aaron Miller, MD